Graft Versus Host Disease
Conditions
Interventions
Group 1:
Group 2:
Sponsors
Medical Center of Hematology, Xinqiao Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria of patients in the experimental group: (1) No age limit, no gender limit; (2) Patients diagnosed with chronic GVHD according to the 2014 US NIH criteria for more than 100 days after allogeneic transplantation; (3) The underlying disease is stable, without progression or recurrence; (4) No active or chronic infection; 2. Inclusion criteria for patients in the control group: (1) No age limit, no gender limit; (2) Patients who have not developed chronic GVHD for more than 100 days after allogeneic transplantation; (3) The underlying disease is stable, without progression or recurrence; (4) No active or chronic infection.
Exclusion criteria
Exclusion criteria: 1. Exclusion criteria for patients in the experimental group: (1) The underlying disease progresses or recurs; (2) active or chronic infection; 2. Exclusion criteria for patients in the control group: (1) Clinical or biopsy-proven chronic GVHD manifestations; (2) Active or chronic infection occurs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the expression level of CCL17;different genotypes of rs223899 at CCL17;the changes of T lymphocyte subsets; | — |
Countries
China
Contacts
Public ContactChen Ting
Medical Center of Hematology, Xinqiao Hospital of Army Medical University
Outcome results
None listed